Form D · Biotechnology
CaraVan Biologix, Inc.
Andover, NJ · CIK 0001837437
Offering snapshot reported Mar 22, 2022 · SEC filing
- Reported sold
- $1.72M Offering amount: $5M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 7, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 22, 2022 | Initial | $1,718,840 | No comparison | 12 | SEC filing |
| Dec 28, 2020 | Initial | $390,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-438398
Source: Form D, filed Mar 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Llew Keltner | Director |
| Thomas Malcolm | Director, Executive |
| Michael Martino | Director |
| Jeffrey Riley | Director, Executive |
| David Rowe | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6 Sunny Lane
Andover, NJ, 07821
Andover, NJ, 07821